HIV resistance in men who have sex with men: a Meta-analysis

Abstract

To assess the prevalence of HIV primary drug resistance and drug resistance gene mutations among men who have sex with men (MSM). Methods: We searched eight electronic databases (CNKI, VIP, CBM, Wanfang Database, PubMed, Web of Knowledge, Springer, Medline) for the studies of HIV drug resistance relevant to MSM. Drug resistance and drug resistance mutations data were pooled and analyzed according to statistical test of homogeneity. Subgroups were further divided according to sample size, location, race, quality rating score, sampling time. Results: Forty-three studies were included in this Meta-analysis. The pooled rate of total to protease inhibitor (PI), nucleoside reverse transcriptase inhibitor(NRTI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) were 10.21% (95% CI 8.65% to12.03%), 2.98% (95% CI 2.25% to 3.93%), 4.05% (95% CI 3.14% to 5.21%), 4.42% (95% CI 3.31% to 5.88%), respectively. The pooled rates of PI major mutation, PI secondary mutations, NRTI mutations and NNRTI mutations were 0.55% (95% CI 0.38% to 0.80%), 1.31% (95% CI 0.98% to 1.75%), 0.85% (95% CI 0.51% to 1.40%), 1.19% (95% CI 0.70% to 2.01%), 0.79% (95% CI 0.55% to 1.13%), 1.73% (95% CI 1.21% to 2.46%), 0.86% (95% CI 0.61% to 1.21%), 2.24% (95% CI 1.77% to 2.83%), respectively. Sample size, region, and race were heterogeneous sources; the rate of resistance mutations and gene mutation rate were different in different subgroups. Conclusion: The prevalence of primary drug resistance among MSM was high in Americas and Europe, and it was gradually increased in Asia. We should pay attention to the high incidence of PI secondary mutations.